lassa
fever
lf
sever
viral
hemorrhag
fever
caus
lassa
viru
lasv
lf
program
kenema
govern
hospit
kgh
eastern
sierra
leon
current
provid
diagnost
servic
clinic
care
suspect
lf
case
per
year
nearli
twothird
suspect
lf
patient
present
lf
ward
test
neg
either
lasv
antigen
antilasv
immunoglobulin
igm
therefor
consid
nonlassa
febril
ill
nlfi
nlfi
patient
studi
gener
sever
ill
account
high
case
fatal
rate
current
studi
aim
determin
possibl
caus
sever
febril
ill
nonlf
case
present
kgh
includ
possibl
involv
filovirus
seropreval
survey
employ
commerci
enzymelink
immunosorb
assay
test
reveal
signific
igm
igg
reactiv
dengu
viru
chikungunya
viru
west
nile
viru
wnv
leptospira
typhu
polymeras
chain
reactionbas
survey
use
sera
subject
acut
lf
evid
prior
lasv
exposur
nlfi
reveal
widespread
infect
plasmodium
falciparum
malaria
febril
patient
wnv
rna
detect
subset
patient
nt
amplicon
specif
filovir
l
segment
rna
detect
low
level
singl
patient
howev
patient
present
kgh
includ
survey
regist
antiebola
viru
ebov
igg
igm
suggest
prior
exposur
agent
ebola
viru
diseas
evd
outbreak
alreadi
deadliest
wide
dispers
outbreak
kind
record
serolog
evid
report
possibl
human
exposur
filovirus
sierra
leon
prior
current
evd
outbreak
support
genet
analysi
ebov
may
present
west
africa
time
prior
outbreak
l
assa
fever
lf
sever
viral
hemorrhag
fever
vhf
caus
lassa
viru
lasv
first
identifi
nigeria
subsequ
identifi
sierra
leon
outbreak
town
panguma
locat
eastern
provinc
sierra
leon
start
late
continu
kenema
govern
hospit
kgh
hospit
locat
heart
lf
endem
zone
sierra
leon
primari
studi
site
lf
research
kgh
lf
program
repres
success
partnership
sierra
leon
ministri
health
sanit
moh
unit
state
center
diseas
control
prevent
partner
much
author
knowledg
lf
vhf
gener
come
studi
conduct
kgh
affili
site
period
follow
end
civil
conflict
sierra
leon
divers
group
organ
includ
sierra
leon
moh
world
health
organ
unit
state
offic
foreign
disast
assist
unit
state
armi
medic
research
institut
infecti
diseas
usamriid
tulan
univers
partner
viral
hemorrhag
fever
consortium
vhfc
reinstat
lf
clinic
laboratori
research
program
kgh
major
aim
effort
enhanc
laboratori
diagnost
capac
train
develop
nation
region
prevent
control
strategi
lf
perform
studi
clinic
manag
infect
environment
control
effort
toward
infect
environment
control
greatli
improv
sinc
cessat
civil
conflict
yet
number
suspect
case
present
kgh
increas
due
part
effort
kgh
lf
outreach
team
educ
healthcar
provid
rural
health
center
lf
threat
alert
renew
avail
free
lf
test
treatment
kgh
current
lf
program
kgh
provid
diagnost
servic
clinic
care
suspect
lf
case
per
year
routin
laboratori
test
lf
use
recombin
antigen
immunoassay
implement
sinc
continu
improv
lf
laboratori
lfl
test
kgh
includ
develop
refin
recombin
antigen
enzymelink
immunosorb
assay
elisa
detect
lasv
antigen
viremia
lasvspecif
immunoglobulin
igm
immunoglobulin
g
igg
later
flow
immunoassay
lfi
implement
boisen
et
al
improv
diagnosi
lassa
fever
use
relasv
lf
immunoassay
prepar
simplic
low
cost
widespread
use
varieti
clinic
field
set
particularli
region
electr
resourc
routin
avail
lfi
term
relasv
antigen
rapid
test
develop
corgenix
inc
ce
mark
earli
anoth
vhf
first
document
west
africa
multipl
case
ebola
viru
diseas
evd
sever
vhf
caus
ebola
viru
ebov
recent
describ
west
africa
first
report
case
filoviru
diseas
west
african
subregion
except
singl
nonfat
case
diseas
caus
forest
viru
report
ivori
coast
seen
outbreak
first
evd
case
detect
guinea
town
near
sierra
leonean
liberian
border
kissi
kingdom
earli
februari
evd
subsequ
spread
region
guinea
includ
capit
citi
conakri
locat
southwestern
region
evd
case
also
report
liberia
initi
north
border
area
first
report
case
guinea
later
capit
citi
monrovia
sierra
leon
report
first
laboratoryconfirm
evd
case
may
case
diagnos
augustin
goba
director
kgh
lfl
west
african
outbreak
sinc
expand
deadli
geograph
dispers
evd
outbreak
record
date
decemb
total
case
count
laboratori
confirm
probabl
suspect
case
evd
report
sierra
leon
confirm
probabl
suspect
death
total
case
count
guinea
liberia
sierra
leon
nigeria
seneg
mali
spain
unit
state
stand
death
among
patient
meet
case
definit
lf
evalu
kgh
lassa
ward
lasv
antigenem
time
span
suspect
lf
patient
test
neg
either
lasv
antigen
antilasv
igm
therefor
consid
nonlassa
febril
ill
nlfi
nlfi
patient
similar
rang
morbid
acut
lf
case
account
high
case
fatal
rate
cfr
observ
prior
studi
studi
aim
determin
caus
febril
ill
nonlf
case
present
kgh
report
includ
possibl
involv
filovirus
prior
outbreak
evd
west
africa
author
initi
develop
evd
immunoassay
support
niaid
sbir
phase
grant
guid
experi
lf
immunoassay
genet
analys
strain
emerg
west
africa
suggest
ebov
forest
guinea
sever
decad
guinean
rainforest
extend
south
liberia
sierra
leon
evok
possibl
prior
human
exposur
ebov
three
countri
therefor
serum
sampl
test
nlfi
patient
presenc
nonlassa
febril
agent
includ
arbovirus
filovirus
evid
report
possibl
human
exposur
ebov
sierra
leon
prior
current
evd
outbreak
clinic
research
includ
human
subject
test
kgh
approv
sierra
leon
ethic
scientif
review
committe
suspect
lf
case
close
contact
confirm
case
elig
enrol
studi
outlin
studi
protocol
approv
tulan
univers
institut
review
board
irb
follow
nation
institut
healthnat
institut
allergi
infecti
diseas
nihniaid
guidelin
govern
use
human
subject
research
subject
studi
provid
written
inform
consent
case
detail
publish
subject
provid
explicit
inform
consent
sampl
test
presenc
diseas
agent
besid
lasv
human
immunodefici
viru
hepat
viru
test
perform
due
irb
ethic
committe
consider
kgh
staff
involv
administr
healthcar
patient
kgh
lassa
ward
medic
decis
includ
whether
administ
ribavirin
patient
sole
discret
attend
kgh
lassa
ward
physician
small
blood
volum
typic
ml
serum
separ
collect
studi
subject
vacutain
tube
experienc
phlebotomist
blood
allow
coagul
min
room
temperatur
serum
separ
coagul
blood
centrifug
g
min
room
temperatur
aliquot
serum
fraction
use
immedi
test
remain
serum
store
cryovial
futur
use
suspect
lf
patient
enrol
clinic
studi
preadmiss
evalu
determin
present
suffici
sign
febril
ill
tabl
contact
suspect
lf
patient
also
elig
enrol
suspect
lf
case
definit
report
document
temperatur
week
absenc
local
inflamm
least
two
major
one
major
plu
two
minor
least
three
minor
sign
symptom
classic
lf
infect
upon
enrol
patient
receiv
admiss
exam
lassa
ward
screen
lf
use
relasv
antigen
rapid
test
elisa
assay
often
within
h
admiss
rapid
test
design
accept
either
whole
blood
finger
stick
plasma
serum
patient
serum
collect
aliquot
perform
relasv
ag
elisa
relasv
igmigg
elisa
serum
also
use
metabol
panel
serum
cytokin
level
test
lasv
revers
transcript
polymeras
chain
reaction
rtpcr
onsit
lfl
test
result
use
aid
assess
acut
lf
conjunct
clinic
sign
symptom
exclus
criteria
includ
hemodynam
instabl
determin
treat
physician
studi
perform
januari
februari
kinet
serum
analyt
analyz
panel
patient
sera
use
piccolo
blood
chemistri
analyz
abaxi
inc
comprehens
metabol
reagent
disc
analyt
character
studi
sodium
na
potassium
k
bicarbon
tco
chlorid
cl
calcium
ca
blood
urea
nitrogen
bun
creatinin
cre
alkalin
phosphatas
alp
alanin
transaminas
alt
aspart
transaminas
ast
total
bilirubin
tbil
albumin
alb
total
protein
tp
data
output
print
patient
sampl
standard
clinic
valu
deviat
record
seri
nlfi
patient
sera
fever
unknown
origin
fuo
select
test
base
appar
morbid
symptomat
patient
identifi
lassa
program
databas
base
cumul
symptom
patient
moder
high
symptom
frequenc
select
part
base
volum
avail
sampl
perform
numer
assay
total
sera
analyz
nonlf
tropic
diseas
elisa
kit
accord
manufactur
instruct
fuo
test
includ
denv
antigen
igmigg
inbio
west
nile
viru
igmigg
inbio
chikungunya
igm
igg
genway
typhu
igmigg
genway
leptospira
igm
core
diagnost
assay
perform
monitor
use
intern
control
cutoff
determin
accord
manufactur
instruct
individu
kit
kinet
serum
cytokin
analyz
flow
cytometri
subpanel
patient
sera
origin
panel
sera
sampl
contain
enough
volum
permit
accur
assess
serum
cytokin
level
serum
cytokin
captur
beadbas
platform
use
ebiosci
flowcytomix
human
kit
bender
medsystem
gmbh
accord
manufactur
instruct
sampl
data
collect
accuri
benchtop
cytomet
accuri
cytomet
inc
raw
fac
data
file
analyz
flowcytomix
pro
softwar
applic
ebiosci
data
report
pgml
input
serum
volum
panel
fevercaus
agent
histor
seropreval
sporad
emerg
endem
statu
western
africa
chosen
screen
viral
microbi
agent
present
subject
acut
lf
previou
exposur
lasv
nlfi
pcr
analysi
perform
origin
panel
sera
due
lack
sampl
volum
remain
sera
agent
analyz
pcr
survey
lasv
zair
ebolaviru
ebov
marburg
viru
mbgv
crimeancongo
hemorrhag
fever
viru
cchfv
rift
valley
fever
viru
rvfv
dengu
viru
denv
yellow
fever
viru
yfv
west
nile
viru
wnv
chikungunya
viru
chikv
leptospira
interrogan
rickettsia
prowasekii
salmonella
typhi
bacillu
recurrenti
plasmodium
falciparum
plasmodium
vivax
infecti
agent
familyspecif
oligonucleotid
correspond
minigen
amplicon
identifi
publish
literatur
inclus
criteria
pcr
methodolog
use
studi
previou
test
live
agent
obtain
vitro
vivo
sourc
valid
nearest
neighbor
test
control
studi
characterist
sourc
oligonucleotid
employ
studi
outlin
supplementari
tabl
nucleic
acid
isol
patient
serum
use
either
qiagen
qiamp
viral
rna
mini
kit
genom
dna
isol
kit
qiagen
oligonucleotid
buffer
amplif
condit
previous
describ
correspond
literatur
refer
prior
adapt
pcr
protocol
screen
fuo
patient
nucleic
acid
method
valid
agentspecif
vitro
gener
rna
transcript
dna
minigen
clone
plasmid
vector
synthes
integr
dna
technolog
rna
transcript
gener
runoff
vitro
transcript
reaction
use
rna
polymeras
sap
ilinear
plasmid
clone
target
amplicon
rna
subsequ
purifi
sepharos
column
resuspend
depc
water
analysi
unrestrict
dilut
plasmid
solut
contain
target
dna
sequenc
use
directli
pcr
reaction
pcr
protocol
valid
target
rna
dna
spike
normal
human
serum
lgml
extract
kit
indic
nucleic
acid
input
use
pcr
reaction
use
manufactur
suggest
condit
modif
suggest
procedur
outlin
literatur
refer
amplif
rna
target
perform
use
superscript
iii
onestep
rtpcr
kit
invitrogen
amplif
dna
target
perform
amplitaq
gold
dna
polymeras
master
mix
invitrogen
amplifi
nucleic
acid
resolv
egel
alongsid
bp
ladder
relev
control
digit
record
analysi
patient
nucleic
acid
sampl
subsequ
isol
manner
pcr
perform
condit
plasmid
dna
construct
isol
character
tulan
univers
transport
kgh
lfw
cold
pack
vitro
transcript
reaction
rna
purif
perform
kgh
lfl
prior
use
pcr
assay
posit
neg
rna
dna
control
purifi
freshli
use
set
pcr
reaction
pcr
run
includ
posit
neg
control
nucleic
acid
neg
control
specif
design
test
contamin
extract
purif
reagent
pcr
buffer
oligonucleotid
polymeras
stock
relasv
iggigm
elisa
test
kit
util
microwel
plate
coat
lasv
nucleoprotein
vybion
inc
boisen
et
al
improv
diagnosi
lassa
fever
use
relasv
lf
immunoassay
prepar
kit
includ
normal
human
serum
control
convalesc
patient
serum
use
refer
curv
posit
control
refer
serum
control
patient
serum
dilut
sampl
buffer
refer
serum
addit
dilut
threefold
describ
dilut
refer
control
sampl
transfer
microwel
plate
llwell
incub
min
ambient
temperatur
microwel
wash
four
time
llwell
phosoph
buffer
salin
pb
tween
wash
solut
peroxidas
label
hu
igg
igm
fcspecif
caprin
polyclon
reagent
jackson
immunoresearch
lab
inc
ad
microwel
llwell
incub
ambient
temperatur
min
microwel
wash
four
time
llwell
pbstween
wash
solut
tmb
substrat
biofx
laboratori
inc
ad
llwell
incub
min
stop
solut
llwell
ad
micropl
read
nm
nm
subtract
posit
cutoff
boisen
et
al
structur
protein
coat
high
bind
microwel
plate
stabil
proprietari
block
solut
test
protocol
similar
relasv
igg
igm
elisa
describ
posit
cutoff
optic
densiti
od
nm
establish
percentil
obtain
panel
normal
sera
sl
donor
n
evd
convalesc
serum
use
interassay
refer
sampl
refer
serum
dilut
follow
serial
threefold
dilut
test
along
normal
human
serum
control
addit
dr
saphir
burton
scripp
research
institut
made
avail
ebov
gp
specif
human
monoclon
antibodi
use
addit
ebov
igg
refer
sampl
studi
perform
june
shortli
first
case
evd
diagnos
kgh
lfl
may
data
analyz
use
sa
sa
institut
inc
hypothes
involv
dichotom
respons
variabl
test
use
fisher
exact
test
logist
regress
logist
regress
model
multipl
independ
predictor
pairwis
interact
term
includ
model
count
outcom
model
use
poisson
regress
distribut
comparison
carri
use
kolmogorovsmirnov
approach
gaussian
kernel
smooth
use
smooth
categor
serostatu
age
distribut
analys
twotail
signific
threshold
set
p
diagnosi
hemorrhag
fever
evd
lf
challeng
fact
present
syndrom
nonspecif
broad
differenti
diagnosi
malaria
typhoid
fever
yellow
fever
leptospirosi
meningococcemia
rickettsi
infect
bacteri
sepsi
mani
ill
confus
vhf
earli
stage
diseas
present
even
experienc
clinician
may
difficulti
distinguish
evd
lf
earli
stage
may
misdiagnos
diseas
clinic
ground
common
febril
ill
determin
pathogen
may
mistaken
lf
sierra
leon
seri
serum
sampl
nlfi
examin
test
variou
serolog
clinic
paramet
result
compar
sampl
patient
acut
lf
well
evid
previou
lasv
exposur
symptomat
patient
provid
inform
consent
identifi
lf
program
databas
base
cumul
symptom
subject
met
lf
surveil
case
definit
previous
discuss
khan
et
al
patient
moder
high
symptom
frequenc
select
part
base
volum
avail
sampl
perform
numer
assay
describ
patient
subdivid
three
group
depend
test
result
relasv
rapid
test
immunoassay
subject
present
kgh
lassa
ward
lasv
antigenemia
classifi
acut
lf
subject
circul
antilasv
igm
consid
lassa
prior
exposur
lpe
discuss
previous
lasv
infect
appear
interfer
class
switch
predominantli
igm
predominantli
igg
respons
thu
antigenneg
subject
antilasv
igm
may
infect
lasv
becom
lf
convalesc
prior
present
lassa
ward
nlfi
subject
neither
lasv
antigenemia
antilasv
igm
consid
nlfi
lf
group
higher
mortal
p
either
subject
lpe
nlfi
cfr
group
tabl
overal
mortal
cohort
lower
overal
cfr
subject
examin
author
previou
studi
includ
consent
subject
known
outcom
present
crf
compar
group
studi
acut
lf
lpe
nlfi
lower
cfr
current
studi
like
due
part
lack
suffici
serum
volum
studi
bias
studi
nonfat
case
compar
overal
patient
cohort
subject
three
group
present
similar
symptom
rang
morbid
frequent
symptom
group
fever
weak
headach
vomit
cough
tabl
valu
clinic
chemistri
also
similar
three
subject
group
tabl
lf
patient
elev
level
ast
alt
enzym
found
liver
cardiac
skelet
muscl
kidney
brain
red
blood
cell
indic
organ
dysfunct
trauma
differ
statist
signific
compar
elev
lpe
nlfi
group
previou
studi
found
ast
alt
significantli
elev
subject
acut
lf
compar
lpe
nlfi
group
lack
signific
current
studi
appear
due
small
sampl
size
tp
significantli
elev
nlfi
compar
lf
lpe
group
level
tp
lf
patient
also
high
therefor
marker
limit
diagnost
prognost
valu
result
indic
lf
diagnosi
base
clinic
symptom
blood
chemistri
alon
order
confound
nlfi
present
similar
symptom
use
immunodiagnost
test
provid
clearer
method
differenti
lf
patient
nonlf
patient
serum
cytokin
level
acut
lf
patient
subject
prior
exposur
lasv
patient
nlfi
number
studi
shown
level
variou
cytokin
chemokin
alter
lasv
infect
exposur
human
nonhuman
primat
explor
possibl
cytokin
alter
might
diagnost
potenti
distinguish
acut
lf
patient
subject
prior
exposur
lasv
patient
nlfi
select
cytokin
measur
use
commerci
assay
reagent
result
stratifi
patient
fatal
nonfat
outcom
certain
cytokin
show
differ
level
acut
lf
lpe
nlfi
tabl
interferon
gamma
ifnc
significantli
elev
fatal
lf
case
lf
compar
fatal
case
lpe
nlfi
significantli
elev
subject
prior
lasv
exposur
die
compar
acut
lf
patient
subject
nlfi
presenc
potenti
febril
diseas
agent
subject
acut
lf
prior
lasv
exposur
nlfi
fortyon
sera
screen
rtpcr
convent
pcr
use
panel
oligonucleotid
design
specif
detect
amplicon
febril
agent
nine
sera
test
posit
lasv
six
wnv
posit
p
falciparum
posit
singl
patient
sampl
posit
nt
amplicon
correspond
conserv
filovir
l
gene
segment
tabl
fig
five
sampl
test
posit
one
patient
test
posit
lassa
viru
lasv
p
falciparum
anoth
tripl
posit
lasv
wnv
p
falciparum
one
patient
studi
low
level
p
falciparum
antigen
test
posit
filovir
revers
transcript
rt
pcr
screen
posit
control
rna
gener
runoff
vitro
transcript
reaction
promot
immedi
upstream
correspond
amplicon
posit
control
p
falciparum
dna
amplifi
clone
nt
rna
gene
fragment
gener
distinct
amplicon
p
vivax
rna
cdna
subset
pcr
reaction
includ
neg
control
rna
dna
isol
normal
neg
serum
unit
state
sierra
leon
origin
well
master
pcr
mix
contain
oligonucleotid
without
input
nucleic
acid
clariti
panel
display
singl
filovir
amplicon
bright
contrast
enhanc
origin
imag
shown
enhanc
panel
panel
shown
origin
captur
outcom
aliv
deceas
bleed
n
bleed
bleed
statu
patient
shown
set
panel
ten
repres
pcr
screen
profil
shown
complet
profil
pcr
screen
display
supplementari
tabl
tabl
fig
studi
identifi
p
vivax
posit
malaria
although
least
one
patient
parasit
identifi
time
period
studi
unpublish
result
studi
identifi
nucleic
acid
serum
fuo
patient
correspond
yfv
denv
chikv
cchf
rfv
typhi
leptospira
int
rfa
r
prowasekii
b
recurrenti
amplicon
prior
exposur
subject
acut
lf
prior
lasv
exposur
nlfi
addit
potenti
febril
agent
nonlf
tropic
diseas
elisa
kit
test
serum
panel
accord
manufactur
instruct
igm
igg
reactiv
record
lf
lpe
nlfi
patient
denv
chikv
wnv
salmonella
typhu
antigen
igm
leptospira
without
statist
signific
classif
group
tabl
signific
proport
subject
test
igm
andor
igg
posit
one
agent
supplementari
tabl
three
patient
data
set
regist
igm
respons
least
one
agent
none
six
patient
sera
test
posit
wnv
pcr
score
posit
respons
wnv
igm
igg
elisa
suggest
activ
wnv
infect
seroconvert
time
present
supplementari
tabl
lasv
igg
seroposit
rate
higher
lpe
nlfi
respect
compar
lf
suggest
patient
prior
exposur
lasv
acut
lf
patient
also
exhibit
posit
igm
igg
respons
denv
respect
chikv
plot
display
mean
raw
data
obtain
titrat
rang
ebov
gpspecif
antibodi
green
bar
neg
control
serum
orang
bar
dilut
patient
serum
blue
bar
cutoff
od
nm
result
posit
rate
sampl
regist
igg
antibodi
specif
ebov
protein
gp
signific
correl
increas
igg
titer
tempor
present
subject
kgh
lassa
ward
could
establish
r
data
shown
tempor
distribut
sera
analyz
midseptemb
late
april
correspond
dri
raini
season
averag
temperatur
graphic
repres
sierra
leon
dri
raini
season
correl
specif
agricultur
activ
main
plant
season
apriljuli
harvest
occur
septemb
januari
agricultur
activ
increas
contact
human
anim
speci
field
wood
area
studi
identifi
obviou
correl
season
emerg
seroreact
ebov
antigen
color
imag
avail
onlin
wwwliebertpubcomvim
leptospira
igm
wnv
typhu
preval
antibodi
respons
agent
reflect
cocircul
pathogen
potenti
coinfect
despit
rel
small
sampl
size
result
point
signific
endem
rate
compet
ill
howev
possibl
crossreact
within
arboviru
flaviviru
assay
may
contribut
result
report
studi
exampl
chikv
posit
may
reflect
prior
infect
onyongnyong
viru
onnv
relat
separ
alphaviru
potenti
exposur
subject
nlfi
filoviru
phylogen
analysi
ebov
isol
emerg
west
african
countri
guinea
sierra
leon
liberia
suggest
ebov
guinean
rain
forest
sever
decad
determin
possibl
human
exposur
filovirus
may
occur
prior
current
outbreak
serosurvey
tabl
fuo
studi
also
analyz
retrospect
ebov
igg
studi
serum
sampl
test
posit
filovirusspecif
pcr
januari
avail
test
ebov
iggigm
elisa
prevent
character
potenti
earli
case
ebov
infect
without
acut
manifest
evd
remain
serum
volum
also
suffici
permit
reamplif
filovir
sequenc
clone
select
amplicon
deep
sequenc
analysi
patient
sierra
leonean
femal
present
kgh
lfw
anoth
kgh
ward
suspect
lf
case
present
fever
weak
dizzi
retrostern
pain
bleed
time
present
kgh
lfw
januari
follow
diagnosi
nlfi
patient
admit
follow
suspect
vhf
case
patient
lasv
antigenneg
lfi
elisa
pcr
neg
p
falciparum
wnv
pcr
screen
regist
posit
titer
lasv
igm
denv
igg
chikv
igm
wnv
igm
igg
typhu
igm
serum
cytokin
profil
unremark
regist
low
level
pgml
pgml
respect
subset
sampl
collect
earli
prior
identif
evd
outbreak
sierra
leon
character
igm
igg
reactiv
ebov
gp
antigen
independ
supplementari
fig
gener
correl
observ
igm
igg
reactiv
gp
antigen
subset
sera
test
patient
regist
signific
igm
reactiv
antigen
without
correspond
measur
igg
titer
supplementari
fig
b
patient
regist
signific
igm
titer
igg
igg
titer
gp
igm
patient
regist
igg
titer
seri
sequenti
serum
sampl
avail
patient
drawn
throughout
stay
kgh
lfw
analysi
igm
igg
reactiv
given
patient
time
provid
valuabl
inform
seroconvers
given
infecti
agent
four
sequenti
serum
sampl
analyz
patient
show
consist
gp
igg
throughout
test
time
frame
supplementari
fig
b
overal
sampl
size
permit
extrapol
signific
seroconvers
trend
provid
valuabl
insight
futur
studi
subject
includ
studi
met
case
definit
lf
patient
gener
sever
ill
irrespect
whether
diagnos
lf
account
cfr
observ
lpe
group
agigm
nlfi
agigm
group
sign
symptom
alon
suffici
provid
clinic
diagnosi
vhf
also
differ
clinic
chemistri
measur
could
use
distinguish
acut
lf
patient
easili
group
elev
ast
lf
tp
lpe
marker
may
offer
clinic
guidanc
diagnost
certain
cytokin
show
differ
level
acut
lf
lpe
nlfi
ifnc
significantli
elev
fatal
case
lf
compar
fatal
case
lpe
nlfi
focus
research
cytokin
level
lf
vhf
like
suggest
possibl
treatment
strategi
howev
routin
cytokin
analysi
feasibl
lf
treatment
center
broad
applic
find
vhf
diagnost
purpos
limit
overal
studi
suggest
specif
diagnost
assay
rather
clinic
observ
laboratori
measur
distinguish
lf
caus
seriou
febril
ill
region
current
studi
provid
insight
pathogen
may
respons
caus
nlfi
patient
present
kgh
lassa
ward
despit
antimalari
treatment
found
subject
present
evid
lpe
nlfi
detect
level
p
falciparum
dna
pcr
lf
patient
group
lf
patient
also
pcrdetect
level
p
falciparum
blood
nearli
patient
unrespons
antimalari
therapi
remain
ill
drugresist
strain
malaria
parasit
circul
west
africa
concern
selfprescrib
use
expir
inact
antimalari
region
studi
parasit
burden
lf
febril
ill
patient
need
studi
need
determin
whether
parasit
burden
detect
pcr
may
suffici
induc
vhflike
sign
symptom
precipit
subject
seek
medic
attent
overal
subject
present
kgh
lassa
ward
detect
rna
blood
amplifi
wnvspecif
primer
studi
requir
determin
whether
rna
detect
specif
wnv
relat
flaviviru
confirm
whether
import
pathogen
respons
febril
diseas
burden
region
sierra
leon
acut
infect
yfv
detect
cohort
test
although
yfv
known
present
sierra
leon
yfv
vaccin
program
implement
subregion
although
proof
yfv
vaccin
requir
prior
entri
foreign
sierra
leon
two
case
yfv
sinc
detect
among
patient
present
lassa
ward
kgh
unpublish
data
pcr
screen
use
oligonucleotid
specif
denv
chikv
rvf
cchf
typhi
lepto
int
rfa
r
prowasekii
b
recurrenti
reveal
relat
pathogen
panel
sera
test
exclud
possibl
agent
signific
caus
febril
ill
subject
present
vhf
ward
kgh
requir
examin
larger
cohort
moreov
may
appropri
analyz
sampl
type
instanc
case
typhi
may
appropri
analyz
stool
sampl
rather
blood
pcr
detect
nucleic
acid
patient
activ
infect
contrast
serolog
studi
detect
recent
past
exposur
accumul
mani
year
therefor
serolog
studi
perform
exposur
flavivirus
arbovirus
febril
ill
subject
present
kgh
high
level
exposur
detect
cohort
denv
wnv
chikv
leptospirosi
typhu
half
subject
test
antiwnv
igg
approxim
onefourth
subject
test
posit
antiwnv
igm
supplementari
tabl
recent
studi
schoepp
et
al
also
detect
serolog
respons
sever
pathogen
use
inhous
develop
assay
usamriid
albeit
lower
level
author
studi
use
commerci
avail
serolog
assay
crossreact
antibodi
may
present
serosurvey
exampl
chikv
posit
may
reflect
prior
infect
onnv
relat
separ
alphaviru
rapid
accur
diagnosi
flavivirus
notori
difficult
due
signific
crossreact
member
famili
name
yfv
wnv
denv
one
sampl
test
present
studi
gener
weak
pcr
product
filoviru
rna
find
signific
patient
present
kgh
lfw
late
year
recent
evd
outbreak
detect
substanti
portion
nlfi
patient
depend
stringenc
immun
assay
cutoff
appli
present
lassa
ward
test
studi
igg
react
ebov
protein
prior
studi
suggest
exposur
filovirus
filoviru
antigen
may
rel
common
commun
central
africa
exampl
becquart
et
al
found
preval
ebovspecif
igg
overal
increas
p
forest
area
sociodemograph
risk
factor
found
antibodi
preval
increas
linearli
year
age
becker
et
al
found
monkey
sera
human
sera
collect
variou
site
germani
react
posit
least
one
three
differ
filoviru
antigen
preval
ebov
antibodi
five
goldpan
villag
situat
northeastern
gabon
studi
found
lower
seropreval
villag
gabon
outsid
recogn
outbreak
area
latter
studi
igg
antibodi
found
igm
antibodi
detect
furthermor
schoepp
et
al
report
preval
igm
reactiv
ebov
mbgv
respect
surprisingli
evid
igg
reactiv
filoviru
protein
note
studi
sampl
analyz
schoepp
et
al
collect
octob
octob
sampl
analyz
current
studi
collect
observ
higher
level
background
reactiv
filoviru
assay
older
sampl
potenti
due
temperatur
fluctuat
storag
result
possibl
sampl
degrad
may
caus
assay
background
noteworthi
sampl
test
schoepp
et
al
provid
vhfc
thu
consist
bank
sampl
collect
year
period
subject
similar
storag
condit
base
phylogenet
analys
ebov
emerg
exposur
sierra
leonean
popul
may
rel
recent
phenomenon
perhap
decad
old
result
current
studi
support
possibl
filoviru
infect
occur
sierra
leon
prior
outbreak
individu
evd
present
health
facil
region
would
high
likelihood
diagnos
anoth
diseas
malaria
clinic
ground
alon
rare
infect
ebov
could
escap
detect
organ
health
surveil
system
place
symptom
similar
diseas
endem
region
case
present
kgh
lf
program
admit
clinic
ground
routin
test
lf
would
reveal
filoviru
infect
outbreak
ebov
detect
eastern
provinc
sierra
leon
recent
decad
despit
activ
surveil
program
lf
vhf
present
indistinguish
case
present
milder
asymptomat
infect
ebov
crossreact
less
virul
avirul
filovirus
could
account
seropreval
observ
studi
fruit
bat
forest
anim
consid
reservoir
ebov
peopl
live
area
may
expos
degrad
otherwis
inactiv
ebov
protein
consumpt
anim
food
contamin
saliva
bat
anim
repeat
exposur
ebov
antigen
without
overt
infect
could
account
seropreval
record
manu
river
region
west
africa
could
endem
two
world
deadliest
virus
thu
futur
laboratori
evalu
peopl
present
sign
symptom
vhf
must
receiv
differenti
diagnosi
lf
evd
drug
treatment
evd
support
care
improv
surviv
fdaapprov
treatment
lf
ribavirin
reduc
mortal
acut
infect
use
earli
infect
studi
nlfi
lf
evd
popul
also
interest
extens
character
report
possibl
due
resourc
infrastructur
constraint
project
period
distinguish
evd
lf
infect
continu
challeng
west
africa
go
forward
two
diseas
requir
distinct
manag
ebovspecif
iggcaptur
assay
use
studi
appear
sensit
specif
robust
work
need
valid
assay
fulli
deriv
commerci
accept
level
sensit
specif
requir
authent
assay
use
serum
sampl
evd
patient
comparison
method
igm
captur
viru
neutral
develop
multiplex
lfi
abil
differenti
lasv
filovirus
way
provid
panel
approach
rapidli
distinguish
among
african
hemorrhag
viru
infect
present
similar
symptom
futur
studi
vhfc
defin
virus
present
febril
ill
patient
make
use
highthroughput
technolog
nextgener
sequenc
ng
ng
alreadi
use
success
diagnost
tool
mean
discov
novel
virus
associ
human
diseas
appli
ng
diagnost
tool
hold
promis
rel
unbias
view
microb
infect
human
requir
priori
knowledg
pathogen
present
also
potenti
elucid
spectrum
diseasecaus
virus
patient
undiagnos
febril
ill
common
occurr
health
clinic
around
world
ng
also
serv
increas
power
surveil
system
detect
infrequ
zoonot
transmiss
potenti
becom
pandem
epidemiolog
studi
ongo
aim
identifi
factor
converg
potenti
transmiss
rapid
dissemin
evd
throughout
western
african
subregion
potenti
index
case
current
evd
outbreak
may
identifi
guinea
recent
report
suggest
ecolog
factor
may
contribut
converg
factor
culmin
ongo
evd
outbreak
manu
river
region
anecdot
report
except
dri
prolong
dri
season
start
sharpli
drier
normal
condit
end
raini
season
may
impact
trigger
transmiss
ebov
natur
host
human
least
one
conclus
may
deriv
current
situat
clear
geograph
expans
increas
humantohuman
transmiss
one
fear
infecti
agent
known
scienc
underway
